|
Tue, 06/17/2025 - 09:09 |
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology |
Relmada Therapeutics |
|
Sat, 06/14/2025 - 13:44 |
Cerebral Palsy Alliance congratulates Professor Andrea Guzzetta, winner of the 2025 Elsass Foundation Research prize |
Cerebral Palsy ... |
|
Fri, 06/06/2025 - 02:05 |
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares |
Trevi Therapeutics |
|
Wed, 06/04/2025 - 02:50 |
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock |
Trevi Therapeutics |
|
Tue, 06/03/2025 - 03:38 |
Trevi Therapeutics Announces Proposed Public Offering of Common Stock |
Trevi Therapeutics |
|
Fri, 05/23/2025 - 11:04 |
Australian first: CPA supports groundbreaking umbilical cord blood treatment for cerebral palsy |
Cerebral Palsy ... |
|
Tue, 05/20/2025 - 20:03 |
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough |
Trevi Therapeutics |
|
Tue, 05/20/2025 - 08:50 |
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals |
Oxis Biotech |
|
Wed, 05/14/2025 - 13:07 |
GT Biopharma Appoints New Member to its Board of Directors |
Oxis Biotech |
|
Sat, 05/03/2025 - 17:57 |
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG |
Regulus Therapeutics |
|
Tue, 04/29/2025 - 17:10 |
Finding Home and Laughter: Sams Life in Supported Independent Living |
Cerebral Palsy ... |
|
Mon, 04/28/2025 - 14:32 |
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 |
Relmada Therapeutics |
|
Thu, 04/24/2025 - 16:05 |
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data |
Relmada Therapeutics |
|
Mon, 04/14/2025 - 09:53 |
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer |
Inhibikase Ther... |
|
Mon, 04/14/2025 - 09:51 |
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
Relmada Therapeutics |
|
Sat, 04/05/2025 - 17:34 |
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit |
Regulus Therapeutics |
|
Thu, 03/27/2025 - 20:57 |
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity |
Inhibikase Ther... |
|
Thu, 03/27/2025 - 18:04 |
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Regulus Therapeutics |
|
Wed, 03/26/2025 - 21:49 |
Resilience and JobsOhio Announce Continued Partnership and Expansion in Blue Ash |
Resilience |
|
Thu, 03/20/2025 - 19:09 |
Currax Secures Reliable and Consistent Supply of CONTRAVE/MYSIMBA with FDA Approval for Second Manufacturing Site |
Currax Pharmace... |
|
Thu, 03/13/2025 - 04:52 |
CPA researchers leading the way at PREMSTEM conference in Barcelona in May 2025 |
Cerebral Palsy ... |
|
Tue, 03/11/2025 - 11:15 |
Currax Pharmaceuticals: Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE/MYSIMBA |
Currax Pharmace... |
|
Mon, 03/10/2025 - 06:21 |
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough |
Trevi Therapeutics |
|
Sun, 03/09/2025 - 17:22 |
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough |
Trevi Therapeutics |
|
Thu, 03/06/2025 - 22:15 |
Celebrating Leadership: Cerebral Palsy Alliances General Manager of Fundraising Honoured on International Womens Day |
Cerebral Palsy ... |
